European Respiratory Society Guideline on various aspects of quality in lung cancer care.

Blum, Torsten Gerriet; Morgan, Rebecca L; Durieux, Valérie; Chorostowska-Wynimko, Joanna; Baldwin, David R; Boyd, Jeanette; Faivre-Finn, Corinne; Galateau-Salle, Françoise; Gamarra, Fernando; Grigoriu, Bogdan; Hardavella, Georgia; Hauptmann, Michael; Jakobsen, Erik; Jovanovic, Dragana; Knaut, Paul; Massard, Gilbert; McPhelim, John; Meert, Anne-Pascale; Milroy, Robert; Muhr, Riccardo; ... (2023). European Respiratory Society Guideline on various aspects of quality in lung cancer care. European respiratory journal, 61(2), p. 2103216. European Respiratory Society 10.1183/13993003.03201-2021

[img]
Preview
Text
13993003.03201-2021.full.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (6MB) | Preview
[img] Text
Blum_EurRespirJ_2023.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (828kB)

This ERS guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO questions. The evidence was appraised in compliance with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Evidence profiles and the GRADE Evidence to Decision frameworks were used to summarise results and to make the decision-making process transparent. A multi-disciplinary task force panel of lung cancer experts formulated and consented the clinical recommendations following thorough discussions of the systematic review results.In particular, we have made recommendations relating to the following quality improvement measures deemed applicable to routine lung cancer care: 1) avoidance of delay in the diagnostic and therapeutic period, 2) the integration of multi-disciplinary teams and multi-disciplinary consultations, 3) the implementation of and adherence to lung cancer guidelines, 4) the benefit of higher institutional/individual volume and advanced specialisation in lung cancer surgery and other procedures, 5) the need for pathological confirmation of lesions in patients with pulmonary lesions and suspected lung cancer, histological subtyping and the molecular characterisation for actionable targets or response to treatment of confirmed lung cancers, 6) the added value of early integration of palliative care teams or specialists, 7) the advantage of integrating specific quality improvement measures, and 8) the benefit of using patient decision tools.These recommendations should be reconsidered and updated, as appropriate, as new evidence becomes available.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin, Tonia, Thomai

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0903-1936

Publisher:

European Respiratory Society

Language:

English

Submitter:

Pubmed Import

Date Deposited:

21 Nov 2022 13:45

Last Modified:

18 Nov 2023 00:25

Publisher DOI:

10.1183/13993003.03201-2021

PubMed ID:

36396145

BORIS DOI:

10.48350/174864

URI:

https://boris.unibe.ch/id/eprint/174864

Actions (login required)

Edit item Edit item
Provide Feedback